Key Presentations on Gastrointestinal Cancers From ASCO 2021

John L. Marshall, MD


June 29, 2021

Dr John Marshall, director of the Ruesch Center for the Cure of Gastrointestinal Cancers in Washington, DC, highlights findings in gastrointestinal (GI) cancers presented at the 2021 annual meeting of the American Society of Clinical Oncology.

Focusing first on upper GI cancers, Dr Marshall discusses studies examining frontline use of immunotherapy. He starts with the ESCORT-1st and CheckMate 648 studies, which underscored the benefit of immunotherapy in squamous cell carcinomas. He also reports on the CheckMate 649 trial, which showed the advantage of chemotherapy plus nivolumab in adenocarcinomas, especially those with higher PD-L1 status. Finally, he touches on the KEYNOTE-811 results with pembrolizumab and trastuzumab in HER2-positive gastroesophageal cancer.

In colorectal cancer, Dr Marshall reports on the final overall survival results of KEYNOTE-177, which favor pembrolizumab as first-line therapy in MSI-high metastatic colon cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.